Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOR Solidarity trial on antiviral drugs for COVID-19
2020-000982-18Phase 3Completed
- Sponsor
- Oslo University Hospital
- Start
- Mar 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of remdesivir and hydroxychloroquine in coronavirus disease 2019 (COVID-19) and bronchopulmonary diseases (3 arms), sponsored by Oslo University Hospital. Primary endpoint: All-cause in-hospital mortality. Started Mar 2020; status: completed.
02
Drugs
remdesivirhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)bronchopulmonary diseases
Beyond the preview
Go deeper on 2020-000982-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000982-18.